Delayed Parkinsonism in Anti‑NMDAR Encephalitis Following Immunotherapy – A Rare Clinical Manifestation
Objective: To describe a rare case of delayed parkinsonism emerging during the recovery phase of anti‑NMDAR encephalitis following immunotherapy in a young adult woman. Background:…AI-driven quantification of oro-facial dyskinesia and kinetic entropy as a predictive biomarker for recovery in paediatric anti-NMDAR encephalitis
Objective: To develop a computer-vision-based machine learning (ML) model to objectively quantify orofacial dyskinesias (ODF) and choreoathetosis in paediatric patients, and to evaluate these "digital…Electroacupuncture Restores Cortico-striatal Synaptic Plasticity by Promoting STEP61 against 6-OHDA Induced Extrasynaptic NMDAR/TRPM4 Complex
Objective: This study investigated whether electroacupuncture (EA) exerted neuroprotection by regulating the physical coupling of extrasynaptic N-methyl-D-aspartate receptor (NMDAR) to the transient receptor potential (TRP)…A Case of Anti-NMDA Receptor Encephalitis Presenting with Refractory Myoclonus and Perioral Dyskinesia during the First Trimester of Pregnancy
Objective: Anti-N-methyl-D-aspartate (NMDA) receptor encephalitis is an autoimmune disorder often presenting with psychiatric symptoms, seizures, and characteristic movement disorders such as orofacial dyskinesia. Its occurrence…Severe Anti-NMDAR Encephalitis After the Covid 19 Cross-vaccination in three young women
Objective: To describe three severe cases of anti-NMDAR encephalitis in young females after the COVID-19 cross-vaccination. Background: Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis is the most recognized…Movement Disorders in Autoimmune Encephalitis a Cohort
Objective: To analyze the clinical profile of patients with suspected autoimmune encephalitis. Background: Autoimmune encephalitis (AE) is a disease characterized by a diverse range of…A Novel Therapeutic Targeting the tPA-NMDAr Interaction for Parkinson’s Disease
Objective: Glunomab, a monoclonal antibody designed to inhibit the interaction between tissue plasminogen activator (tPA) and the N-methyl-D-aspartate receptor (NMDAr), has demonstrated therapeutic potential across…Pharmacokinetics And Safety Of YA-101, A Dual Inhibitors Of D-Amino Acid Oxidase (DAAO) And NLRP3 Inflammasome, In Healthy Subjects: A Double-Blind, Placebo-Controlled, Randomized, Single Dose and Multiple Dose Phase I Study
Objective: To evaluate the safety, tolerability, and pharmacokinetics (PK) profile of YA-101 in healthy volunteers with single dose and multiple dose Background: Multiple System Atrophy…Huntington’s Disease Pathogenesis, Molecular Factors, and Potential for Combinatorial Therapies: A Focus on BDNF and NMDA Receptor Therapies
Objective: This paper outlines current therapeutic options for HD, and ultimately suggests taking a combinatorial therapeutic approach to slow HD progression by simultaneously treating multiple…Complex movement disorder presentations of autoimmune encephalitis – recovery at 4 weeks versus 4 years
Objective: The goal is to learn from different presentations of Autoimmune Encephalitis (AIE) so that we consider the diagnosis more quickly, pursue the work-up judiciously…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.